If I reconstitute a 15 mg vial with 2 mL of phosphate-buffered diluent, what concentration do I end up with?

The particulars: 15 mg · 2 mL · phosphate-buffered diluent.

I would rather understand the derivation than memorise the outcome.

Two people I asked gave two answers that differ by a factor of ten, which is suggestive.

What is the general form of this calculation?

This is not exotic. It is just the difference between doing it deliberately and doing it approximately.

Write the arithmetic on the vial label. It costs nothing and removes the step where you reconstruct it from memory at an inconvenient moment.

In practice, room temperature before drawing is worth the ten minutes. Cold solution is more viscous, draws slower, and is more likely to pull a bubble past the plunger seal.

The general principle — that peptides adsorb and denature at air–liquid and solid–liquid interfaces — is standard formulation science.

The practical summary: fine gauge, gentle swirl, diluent down the wall, room temperature before drawing, and check the syringe scale.

In practice, gentle swirling dissolves a lyophilised cake far better than vigorous shaking, which causes aeration and aggregation.

The order of operations matters: temperature first, then diluent measurement, then injection, then gentle dissolution, then labeling.

Specifically, the practical summary: fine gauge, gentle swirl, diluent down the wall, room temperature before drawing.

Published data on syringe dead space in the context of injection-equipment programmes quantifies low-dead-space designs as retaining under 2 µL against 35 µL or more.

None of this is exotic. It is just the difference between doing it deliberately and doing it approximately.

Put another way, sodium chloride 0.9 per cent as a diluent is not a neutral substitution. Ionic strength affects peptide solubility and aggregation propensity.

A 0.22 µm syringe filter will remove particulates and organisms, and it will also adsorb a fraction of your peptide.

Tilting the vial to pool solution in the corner before the final draw, and giving it a minute to drain down the walls, genuinely recovers ten to twenty microlitres.

Coring of elastomeric closures is a well-characterised failure mode in the parenteral packaging literature.

The caveat is that this is not a recommendation to administer anything. Research-use-only material is not approved for human use.

Do the arithmetic twice, ideally with someone else doing it independently.

More usefully, reconstitution is the step where most hands-on errors enter the system, which is why spending time on technique here pays off more than anywhere else.

On re-freezing something that thawed in transit: if it arrived as a lyophilised solid that warmed but never got wet, re-freezing costs you nothing except the thermal cycle.

The 28-day beyond-use convention for a multiple-withdrawal preserved preparation derives from USP compounding chapters, which set it on microbiological risk rather than chemical stability.

Worth saying: if your arithmetic and someone else's disagree by a factor of ten, one of you has made a unit error.

The practical summary: fine gauge, gentle swirl, diluent down the wall, room temperature before drawing, and check the syringe scale.

Specifically, the distinction that resolves most of these questions is that bacteriostatic water suppresses microbial growth and does not sterilise anything. It buys you a multiple-withdrawal presentation; it does not make an unsterile preparation sterile, and it does not substitute for technique.

Number of stopper piercings matters less than the gauge doing the piercing.

The general principle — that peptides adsorb and denature at air–liquid and solid–liquid interfaces — is standard formulation science.

The caveat on all of this is that it assumes the vial contains what the label says.

None of this is exotic. It is just the difference between doing it deliberately and doing it approximately.